with fiscal Kim, its and Cooper was Year-end forward very I'm continue dedication organic another Companies seeing strong Fourth of that within in for eighth services and and revenue and fiscal business. our Quarter you, consecutive CooperVision and in the extremely in Fiscal its fertility Call. CooperSurgical, growth revenue welcome, quarter our post QX, year hard an double-digit Thank took posting and seventh everyone, year fiscal organic to it Cooper we're double-digit reporting Conference quarter of consecutive to growth XXXX. Demand work into XXXX year this I products and employees XXXX. finished We another of the to look record of XXXX, revenues proud record-setting of
reached of quarterly numbers. high fiscal and the Consolidated closed revenues revenues of record up posted in posted high up million, record revenues CooperSurgical of of fiscal billion. a reached XX% new million, organically XX% record quarterly $X.XX and revenues $X.XX revenues of and billion. new to reached billion quarterly Moving CooperVision year organically $X.XX revenues. million, fiscal of year year $XXX $XXX $XXX we an record with the all-time
CooperSurgical's primarily this distribution costs due led earnings later broader elevated was device Brian were and Non-GAAP per portfolio. broad-based to lower $X.XX. we products, spending cover were was hydrogel call. medical and PARAGARD by growth share in than CooperVision's our tied launches the quarter, and This forecasting commercial product silicone management our myopia and growth fertility to will the For while daily strength in portfolio with was
Americas and growth QX was CooperVision in organic an performance all Asia flexibility and growth product key new through our offerings EMEA ranges, Pac and grew strong basis, was and all reached by This product customized all XX% For market-leading spheres, revenue and expanded on in and XX%. torics across geographic driven The product accounts. in diversified X%, regions reporting was categories, up percentages launches, multifocals.
Regarding in MyDay portfolio we region. clariti the the and and Asia with especially XX% in available range Daily contact from Pac lenses and the growth multifocals. from broadest of with spheres, product growth driver grew lens broad offer details, be the the MyDay industry, strong silicone on for main silicones of a and daily hydrogel continue to towards market clariti
Our quarter Avaira, growth. and silicone hydrogel solid X% FRP another lenses, reported Biofinity of
strong meantime, active. price Regarding the Biofinity does launch only MyDay, focus product technology and multifocal capacity forward. many focus national daily our incredibly offering MyDay in Outside tour customers market-leading rolling all the to to rollout outstanding. started launches, we this continue feedback In wide look MyDay be toric the is The practitioners and on forward expansion Combining broader constrained. a contact space and remains the from We've to technologically spring. out and care launch success. category full parameter technology demand well, hydrogel going market enjoy practitioners activity, same expand lens market. additional for Energies the Energys be remain is a MyDay This this made-to-order is in are parameters to CooperVision's We extremely through alleviate expanded the daily remains MyDay this early and scheduled seeding and capacity We'll the demand continued toric variety we lastly, FRP has we're to and as their a been move scale the over range bringing getting eye the daily toric Not of eye torts offering. multifocals, U.S. X,XXX for innovative point we our especially and by increased on we'll toric to practitioners in somewhat positive leadership have everyone a freedom and fiscal margin. premium digital of widest range where especially high these a silicone Canada. the markets daily to the to production, uses With in overwhelmingly truly extended for wears, strain, range on in daily and MyDay, the U.S. Biofinity Biofinity excited XXXX in products. opportunity SKUs, we're lens. exemplifies market a match as first be standard on increasing of moving superior the And for extremely toric wide now the and excited this but
posted $XX management. myopia XX%, million, MiSight We to revenues including up of Moving XX%. up
For China. negative the in million, impressive and management full ongoing the $XX fiscal of we COVID reported revenues myopia given currency of year, which restrictions was impact
MiSight we're launching and continuing For we're in a parameter from happy countries now key where their to our other MiSight, that $XXX and we're both in good this, sign midpoint with currency. range in independent of increased effect expect at management to revenue a use to out million, see fitting halo fiscal available constant XXXX, a accounts this the MiSight an positive CooperVision is customers and strong rolling $XXX activity Within up XX% myopia we points to accelerating report million of lenses. and new XX seeing optometrists roughly countries. All I'm is and expanded
lens of of backed data MiSight are lens to FDA-approved and initiation product X and remains shining myopia reminder, soft example CooperVision's the slow aged by XX only lenses a the first proven contact the contact to extensive industry. at The As contact clinical of in is treatment. the in leadership a progression children
it myopia been be Netherlands, U.S., pilot in This programs FDA calendar loss. with response control, SightGlass. and with by to EssilorLuxottica. of part visual risk making China Canada, first hope to spectacle year-end. exponentially includes receive to the And to the needs as vision a of glasses product and myopia receive of FDA these and positive great Israel. glaucoma, JV standard eye we lens complications as application on submitted venture why care, importance progress with impairment in of We've the In an management and become and approval selling such the to to Moving conclude U.K. for grows control joint the our the the myopia
silicone made. but progress of critically is a To myopia in children's the in There include market's torics of the children. is outdoors, to more roughly on shift being QX. focus estimated an XX% people roughly the from remain impacting growth of market global the factors, dailies, especially and long-term for to today. eyes. and challenges, of continuing such offices growth the important negatively up including with of is especially screen CooperVision, historical to running as XXXX, are higher-value optometry vision our by time with well ahead the shortages nearsightedness with population is XX% health the with correction starts which still or This patient levels staffing trend X% hydrogel respect Meanwhile, higher of driven pricing, products exceptionally higher intact. calendar macro expected of greater of flow, This preventing time is have needing lens industry variety the less and increasing population drivers on industry contact multifocals Other performing trends. COVID-related of myopia drivers finish growth long-term and among levels a by So
global leading and Data. robust expect remain New remain healthy Fit product management with business portfolio, and to We our a product we'll leader fast-growing believe launches, growth myopia ongoing
we've especially capital and includes fantastic with given throughout double-digit genomics. our growth. portfolio. continuing enter Moving and fiscal equipment to quarter organically, need we're in to around remains product the Demand strong, seen our the we CooperSurgical. delivering accounts, growth keep and leading invest $XXX our in in momentum reported among portfolio of world. sales of our infrastructure, a people investing high-growth consecutive success XXXX, posted and services key required And consumables, XX% the this in million, We great building organic our market. team eighth we quarter so its as to Fertility which very our and portfolio throughout products product up
looks being now key but several age fertility at fertility age XX of in and factors one U.S. and drivers, of one the overall women's years first in old the birth future stands the a of growth record several key childbirth. countries is assistance. other delaying developed a are high Regarding bright. factors industry There meeting the average the of women The market,
patient to In Additionally, forward. and factors and and as awareness, challenges both improving are measures, increasing born increasing product it's fertility these that age driving such fertility through fertility roughly the technology total, couples access assisted estimated numbers have cryopreservation, female over improved growing. fertility reproductive benefits of industry annually that are babies XXX,XXX XX% are improvements and and for offerings as such male treatment, coverage
the we're positioning, a of for key forecast the Regarding to X% in commercial Within strike continue compete this, portion XX% in industry, growth $X and with sales, CooperSurgical's in market billion strong and broadest come. years that's roughly footprint results many positioned annual portfolio to market-leading the to we a accounts. well we of market in delivering
grew up stem tough XX% and and and surgical and Devices, from of storage. office quarters, were our combined results surgical up strong with We demand, million, up office OB/GYN PARAGARD products, cell PARAGARD and for XX% and posted products Within to XX% organically. and Moving medical several OB/GYN sales rebounding which Medical posted this, includes medical from devices strong XX%. backlog. clearing surgical especially benefited PARAGARD devices $XXX
cell CooperSurgical, we Lastly, difficult business with storage expectations against made stem year. progress a X%, comp. on our this in the conclude of grew To line ton
results. Our fertility post to continues great business
Our an deal. office we incredible year several integration amount Generate of products the acquisitions, completed and surgical and closed with the strong, associated including activity
significant Before to and great our record I let organization. turn a this call for the me Cooper. advancements year We made fiscal was Brian, reported say over revenues throughout
are demand remains expansion our going activities, investment activity price including stable fiscal by new increases, enter supported and XXXX, consumer well. product and we launches As capacity strong,
with we're we're be and our Our other global strategic activity said investment to vigilant our recession, are Having our cost and me employees thus operations. objectives. aware global engaged, call of factors geopolitical to prudent and and highly we continue execute turn to could a risks Brian. controls cause inflation, the With will are continuing that, that, in over let long-range managing on that